Drug intelligence / Profile preview

kurarinone

Development stage
Preclinical
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral (preclinical Studies)
01

Overview

Kurarinone is a naturally occurring prenylated flavanone and a major bioactive component isolated from the roots of Sophora flavescens and other related plants[3][6][7]. It exhibits a broad spectrum of pharmacological activities including antitumor (anticancer), anti-inflammatory, neuroprotective (notably in Parkinson’s disease models), anti-drug resistance, antimicrobial (antifungal and antibacterial), antioxidant, estrogenic effects as well as modulation of metabolic enzymes. Mechanistically, kurarinone acts through multiple pathways such as inhibition of Th1/Th17 cell differentiation via immune modulation[1][9], suppression of STAT3 and Akt signaling pathways[3], selective inhibition of soluble epoxide hydrolase (sEH/Ephx2)[5], and inhibition/modulation of cytochrome P450 enzymes and UDP-glucuronosyltransferases[7]. Kurarinone has shown efficacy in preclinical models for cancer chemoprevention and neurodegenerative diseases like Parkinson’s disease by stabilizing epoxyeicosatrienoic acids through sEH inhibition[5].

Other names
2'-Methoxykurarinone(2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-8-(5-methyl-2-prop-1-en-2-ylhex-4-enyl)-2,3-dihydrochromen-4-oneMarini
02

Targets

EPHX2 (Soluble epoxide hydrolase)DRD1 (Dopamine D1 Receptor)AKT (RAC-alpha serine/threonine-protein kinase)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on kurarinone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kurarinone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call